Genelex Corporation

Pharmacogenomics

Volumn 9, Issue 4, 2008, Pages 469-475

  Coleman, Howard ^a   Ashcraft, Kristine ^a  

^a Genelex Corporation   (United States)

Author keywords

Adverse drug reactions; CYP450; Cytochrome; Drug interaction; Personal health records; Personalized medicine; Pharmacogenetics; Pharmacogenomics; Software

Indexed keywords

AMIODARONE; ATOMOXETINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; ENDOXIFEN; FLUOXETINE; IRINOTECAN; MERCAPTOPURINE; PAROXETINE; SERTRALINE; SIMVASTATIN; TAMOXIFEN; TAMOXIFEN DERIVATIVE; THIOPURINE METHYLTRANSFERASE; THIORIDAZINE; VITAMIN K RECEPTOR; VITAMIN RECEPTOR; VORICONAZOLE; WARFARIN;

AREA UNDER THE CURVE; ARTICLE; BLEEDING; BREAST CANCER; COMPUTER PROGRAM; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; ENZYME ACTIVITY; GENETIC ALGORITHM; GENETIC ANALYSIS; HOT FLUSH; HUMAN; MEDICAL DECISION MAKING; NEUTROPENIA; PHARMACOGENETICS;

ANIMALS; DRUG INDUSTRY; DRUG INTERACTIONS; HUMANS; PHARMACOGENETICS; SOFTWARE;

EID: 44949141413     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.4.469     Document Type: Article

References (20)

1. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients - a meta-analysis of prospective studies. JAMA 279, 1200-1205 (1998).
2. Bodenheimer T: Coordinating care - a perilous journey through the health care system. N. Engl. J. Med. 358, 1064-1071 (2008).
3. Ingelman-Sundberg M, Rodrquez-Antona C: Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos. Trans. R. Soc. Lond. B Biol. Sci. B 360, 1563-1570 (2005).
4. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W: Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286(18), 2270-2279 (2001).
5. Eichelbaum M, Ingelman-Sundberg M, Evans WE: Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119-137 (2006).
6. Tomalik-Scharte D, Lazar A, Fuhr U, Kirchheiner J: The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J. 8, 4-15 (2008).
7. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116, 496-526 (2007).
8. Jemal A, Siegel R, Ward E et al.: Cancer statistics 2006. CA Cancer J. Clin. 56, 106-130 (2006).
9. Goetz MP, Rae JM, Suman VJ et al.: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23, 9312-9318 (2005).
10. Goetz MP, Knox SK, Suman VJ et al.: The impact of cytochrome P4502D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101, 113-121 (2007).
11. Jin Y, Desta Z, Steams V et al.: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst. 97, 30-39 (2005).
12. McWilliam A, Lutter R, Nardinelli C Health care savings from personalizing medicine using genetic testing: the case of warfarin. AEI-Brookings Joint Center for Regulatory Studies, Working Paper (2006).
13. Higashi MK, Veenstra DL, Kondo LM, et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690-1698 (2002).
14. Gurwitz D, Mcleod HL: Primum non nocere. Adverse drug events must be taken seriously. Pharmacogenomics 8, 311-314 (2007).
15. Gage BF, Eby C, Milligan PE et al.: Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb. Haemost. 91, 87-94 (2004).
16. Schwarz UI, Ricthie MD, Bradford Y et al.: Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 358 (10), 999-1008
17. Sconce EA, Khan TI, Wynne HA et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 (2005).
18. Hodgson R: Pharmacogenetic clinics in psychiatry: a clinical reality? J. Clin. Psychopharmacol. 20, 246-251 (2000).
19. Ernst FR, Grizzle AJ: Drug-related morbidity and mortality: updating the cost-of-illness model. J. Am. Pharm. Assoc. 41, 192-199 (2001).
20. Zhu Y, Shennan M, Reynolds KK et al.: Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin. Chem. 53, 1199-1205 (2007).